A review of teicoplanin in the treatment of serious neonatal infections

Fanos, Vassilios; Kacet, N.; Mosconi, Giorgio

doi:10.1007/s004310050629

Cited by 31 publications

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of ion suppression is crucial in an LC-MS/MS method, as suppression has been shown to compromise detection selectivity. 32 A calibration curve spanning the therapeutic range of Teicoplanin samples at four concentrations (20,50, 100 and 200 mg/mL) were evaluated for their intra-assay (n ¼ 10) and inter-assay (n ¼ 20) imprecision 25-75 mg/mL was demonstrated to be linear up to 200 mg/mL, and can be consistently reproduced having an r 2 value .0.99. These preliminary steps to ensure both teicoplanin and ristocetin can be reliably measured by LC-MS/MS are of paramount importance so the performance characteristics of the method are suitable and reliable for the intended analytical applications.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a novel method

et al. 2012

View full text Add to dashboard Cite

Background: Teicoplanin is an antibiotic used for the treatment of endocarditis, osteomyelitis, septic arthritis and methicillinresistant Staphylococcus aureus. Teicoplanin is emerging as a suitable alternative antibiotic to vancomycin, where their trough serum levels are monitored by immunoassay routinely. This is the first report detailing the development of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for measuring teicoplanin in patients' serum. Methods: An Acquity TM UPLC (ultra-pressure liquid chromatography) tandem mass spectrometer was used to measure tei-

show abstract

Section: Discussionmentioning

confidence: 99%

“…Imprecision of the method was assessed by the analysis of four QC samples at various concentrations (20,50, 100 200 mg/mL). These samples were analysed 10 times each within a single run to determine intra-assay imprecision, and also analysed in separate batches (n ¼ 20) over a fourweek period to assess inter-assay imprecision.…”

Section: Imprecisionmentioning

confidence: 99%

Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a novel method

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Teicoplanin is used as alternative therapy to vancomycin only in Europe [26,27]. However, some studies have shown an increase in the isolation of CNS with reduced susceptibility to teicoplanin worldwide.…”

Section: Discussionmentioning

confidence: 99%

Heterogeneous resistance to vancomycin and teicoplanin among Staphylococcus spp. isolated from bacteremia

Nunes

Schuenck

Bastos³

et al. 2007

Braz J Infect Dis

View full text Add to dashboard Cite

This study evaluated the BHIA screening method with 4 or 6 μ μ μ μ μg/mL of vancomycin to detect glycopeptides heteroresistant staphylococci strains isolated from bacteremia. A total of 213 staphylococci strains were isolated from 106 patients between October/2001 and November/2002 in a tertiary hospital in Rio de Janeiro city. Fifty-seven (53.8%) patients presented Staphylococcus aureus, while coagulase-negative staphylococci (CNS) were isolated from 49 (46.2%). Resistance rates for oxacillin of 26.3% and 81.6% were found for the staphylococci isolates, respectively. Thirteen CNS isolated from nine (8.5%) patients grew on agar screening with 4 μ μ μ μ μg/mL of vancomycin and showed heterogeneous profiles of resistance for vancomycin and teicoplanin by the population analysis profile method. Only 30.8% of them grew at the concentration 6 μ μ μ μ μg/mL. Bacterial infection and use of antimicrobial therapy were common among these patients. Alert about the emergence of oxacillin-resistant staphylococci presenting heteroresistance to glycopeptides is important in order to achieve judicious use of antimicrobials. Vancomycin agar screening test could help to confirm the presence of these isolates in hospitals.

show abstract

“…5,7 We used this dosage in our patients with high bacteriological cure rates. In a review of non-comparative studies by Fanos et al, 4 the clinical efficacy and bacteriological cure rates were found to be as high as 100%.…”

Section: Discussionmentioning

confidence: 99%

“…1 -3 Several causative organisms of neonatal sepsis have been isolated over the years; currently, Staphylococcus aureus and coagulase-negative staphylococci (CoNS) represent the most frequently isolated nosocomial pathogens from neonates in the NICU. 4,5 These organisms show significant resistance to methicillin and/or aminoglycosides, which may be as high as 70 -90%, thus glycopeptide antibiotics are used in many NICUs. 2,5 -8 Vancomycin is a glycopeptide antibiotic that has been used in nurseries for many years, despite its side-effects.…”

Section: Introductionmentioning

confidence: 99%

Experience with Teicoplanin in the Treatment of Neonatal Staphylococcal Sepsis

et al. 2004

View full text Add to dashboard Cite

We aimed to evaluate retrospectively the clinical and bacteriological efficacy and potential side-effects of teicoplanin treatment in neonates with proven staphylococcal infection. There were 37 episodes of staphylococcal septicaemia in neonates with a mean gestational age of 34.2 ± 2.3 weeks; 26 were caused by coagulasenegative staphylococcal (CoNS) sepsis and 11 by Staphylococcus aureus sepsis. All episodes were treated with teicoplanin (intravenous loading dose 16 mg/kg followed by a maintenance dose of 8 mg/kg daily). The methicillin resistance and antibiotic susceptibilities of both micro-organisms were evaluated. Bacterial eradication was achieved in 89.1% of cases and mortality was 16.2%. The mean duration of treatment of the survivors was 11.6 ± 2.3 days. There were no drug-related adverse events and the biochemical and haematological tests showed no clinically significant changes in relation to teicoplanin therapy. Our results suggest that teicoplanin is highly effective in neonatal staphylococcal sepsis.

show abstract

A review of teicoplanin in the treatment of serious neonatal infections

Abstract: Teicoplanin (8-10 mg/kg) administered intravenously or intramuscularly once daily after a loading-dose regimen of 15-20 mg/kg per day appears to be an effective and well tolerated treatment for Gram-positive infections in neonates.

Cited by 31 publications

References 21 publications

Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a novel method

Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a novel method

Heterogeneous resistance to vancomycin and teicoplanin among Staphylococcus spp. isolated from bacteremia

Experience with Teicoplanin in the Treatment of Neonatal Staphylococcal Sepsis

Contact Info

Product

Resources

About